Axon Enterprise (NASDAQ:AXON) President Sells 16,775 Shares of Stock

Posted by Brenda Bartman on Sep 2nd, 2026

Axon Enterprise, Inc (NASDAQ:AXON – Get Free Report) President Joshua Isner sold 16,775 shares of the firm’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $574.43, for a total value of $9,636,063.25. Following the sale, the president owned 296,974 shares of the company’s stock, valued at $170,590,774.82. The trade was a 5.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joshua Isner also recently made the following trade(s):

On Friday, June 5th, Joshua Isner sold 13,000 shares of Axon Enterprise stock. The stock was sold at an average price of $488.45, for a total transaction of $6,349,850.00.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON traded down $11.32 during trading hours on Wednesday, hitting $506.98. 1,042,743 shares of the company’s stock were exchanged, compared to its average volume of 1,051,964. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $792.16. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80. The stock has a market capitalization of $41.19 billion, a price-to-earnings ratio of 210.37, a PEG ratio of 9.20 and a beta of 1.39. The company’s 50-day moving average price is $565.59 and its 200-day moving average price is $484.77.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The business had revenue of $904.39 million for the quarter, compared to analysts’ expectations of $876.42 million. During the same quarter in the previous year, the firm posted $2.12 earnings per share. The firm’s revenue for the quarter was up 35.3% on a year-over-year basis. On average, sell-side analysts expect that Axon Enterprise, Inc will post 2.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Axon Enterprise

Institutional investors have recently added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV purchased a new stake in Axon Enterprise in the fourth quarter worth $28,000. Keating Financial Advisory Services Inc. bought a new position in Axon Enterprise in the 2nd quarter worth $31,000. AlphaCentric Advisors LLC bought a new stake in shares of Axon Enterprise during the 4th quarter valued at about $34,000. Darwin Wealth Management LLC purchased a new position in shares of Axon Enterprise during the second quarter valued at about $37,000. Finally, Washington Trust Advisors Inc. increased its position in shares of Axon Enterprise by 1,300.0% during the second quarter. Washington Trust Advisors Inc. now owns 70 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 65 shares during the period. 79.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on AXON shares. Needham & Company LLC restated a “buy” rating on shares of Axon Enterprise in a report on Wednesday. Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 10th. Piper Sandler lifted their price objective on shares of Axon Enterprise from $724.00 to $732.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Barclays lifted their price target on shares of Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, July 21st. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $730.92.

Get Our Latest Research Report on Axon Enterprise

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.